Pfizer ends Trillium-related development as R&D spend jumps
Pfizer has discontinued the final clinical study stemming from its 2021 acquisition of Trillium Therapeutics, funneling cash primarily toward a host of other cancer and obesity studies. The company reported in
May 5, 2026 10:41 AM EDT R&DPharma Pfizer cuts final Trillium-related program, but R&D spend jumps on cancer, obesity studies Max Bayer Senior Reporter Pfizer has discontinued the final clinical study stemming from its 2021 acquisition of Trillium Therapeutics, funneling cash primarily toward a host of other cancer and … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that